Collin Gage is the Chief Executive Officer and a Director at ARMR Sciences Inc. After being personally impacted by addiction and overdose, Collin decided to spend his career focused on challenging the status quo and developing innovative new solutions. During this process, he and his partners created ARMR with the mission of developing preventative and protective solutions for the addiction and overdose epidemic. Prior to founding ARMR, Collin was the Senior Vice President of Corporate Development and Investor Relations at Mind Medicine Inc. (NASDAQ: MNMD), a clinical-stage biopharmaceutical company focused on pioneering addiction and mental health treatments. During his tenure at MindMed, he managed firm-wide capital markets strategy, laying the foundation for the company to go on to raise more than $250 million to support late-stage clinical trials. This eventually led to MindMed receiving Breakthrough Therapy Designation from the Food & Drug Administration (FDA). Prior to MindMed, Collin was responsible for researching and investing in innovative early-stage startups at a private family office. In his role, he worked with several venture-backed startups to guide them through complex financial strategies in private and public capital markets. Before this role, Collin worked as a Consultant for Tesla, Inc. (NASDAQ: TSLA), where he was responsible for identifying and executing emerging market growth strategies. Collin began his career as a consultant at Point72 Asset Management, a global multi-strategy asset manager.